These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 8481932)

  • 1. Efficacy and tolerability of 4-hydroxyandrostenedione (4-OHA) as first-line treatment in postmenopausal patients with breast cancer after adjuvant therapy.
    Bajetta E; Zilembo N; Buzzoni R; Noberasco C; Celio L; Bichisao E
    Cancer Treat Rev; 1993 Apr; 19 Suppl B():31-6. PubMed ID: 8481932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of formestane in de novo tamoxifen-resistant patients with metastatic breast cancer.
    Noberasco C; Bajetta E; Zilembo N; Di Leo A; Cappuzzo F; Bartoli C; Bono A; Bichisao E
    Oncology; 1995; 52(6):454-7. PubMed ID: 7478430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aromatase inhibition with 4-hydroxyandrostenedione in the treatment of postmenopausal patients with advanced breast cancer: a phase II study.
    Höffken K; Jonat W; Possinger K; Kölbel M; Kunz T; Wagner H; Becher R; Callies R; Friederich P; Willmanns W
    J Clin Oncol; 1990 May; 8(5):875-80. PubMed ID: 2185341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer.
    Pérez Carrión R; Alberola Candel V; Calabresi F; Michel RT; Santos R; Delozier T; Goss P; Mauriac L; Feuilhade F; Freue M
    Ann Oncol; 1994; 5 Suppl 7():S19-24. PubMed ID: 7873457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formestane. A review of its pharmacological properties and clinical efficacy in the treatment of postmenopausal breast cancer.
    Wiseman LR; Goa KL
    Drugs Aging; 1996 Oct; 9(4):292-306. PubMed ID: 8894526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of advanced breast cancer in postmenopausal women with 4-hydroxyandrostenedione.
    Stein RC; Dowsett M; Hedley A; Davenport J; Gazet JC; Ford HT; Coombes RC
    Cancer Chemother Pharmacol; 1990; 26(1):75-8. PubMed ID: 2322991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report.
    Goss PE; Powles TJ; Dowsett M; Hutchison G; Brodie AM; Gazet JC; Coombes RC
    Cancer Res; 1986 Sep; 46(9):4823-6. PubMed ID: 2942241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial.
    International Breast Cancer Study Group (IBCSG)
    J Natl Cancer Inst; 2002 Jul; 94(14):1054-65. PubMed ID: 12122096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Doxorubicin versus methotrexate both combined with cyclophosphamide, 5-fluorouracil and tamoxifen in postmenopausal patients with advanced breast cancer--a randomised study with more than 10 years follow-up from the Danish Breast Cancer Cooperative Group. Danish Breast Cancer Cooperative Group (DBCG).
    Andersson M; Madsen EL; Overgaard M; Rose C; Dombernowsky P; Mouridsen HT
    Eur J Cancer; 1999 Jan; 35(1):39-46. PubMed ID: 10211086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women's Environment, Cancer and Radiation Epidemiology Study.
    Bertelsen L; Bernstein L; Olsen JH; Mellemkjaer L; Haile RW; Lynch CF; Malone KE; Anton-Culver H; Christensen J; Langholz B; Thomas DC; Begg CB; Capanu M; Ejlertsen B; Stovall M; Boice JD; Shore RE; ; Bernstein JL
    J Natl Cancer Inst; 2008 Jan; 100(1):32-40. PubMed ID: 18159070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patients.
    Dowsett M; Stein RC; Coombes RC
    J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):155-9. PubMed ID: 1388047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second generation aromatase inhibitor--4-hydroxyandrostenedione.
    Dowsett M; Coombes RC
    Breast Cancer Res Treat; 1994; 30(1):81-7. PubMed ID: 7949207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Aromatase inhibitors in adjuvant setting in breast cancer].
    Spano JP; Khayat D; Delozier T
    Bull Cancer; 2004 Dec; 91 Suppl 4():S239-43. PubMed ID: 15899615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route.
    Dowsett M; Goss PE; Powles TJ; Hutchinson G; Brodie AM; Jeffcoate SL; Coombes RC
    Cancer Res; 1987 Apr; 47(7):1957-61. PubMed ID: 3815384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of adjuvant chemotherapy on outcome after relapse for patients with breast cancer.
    Houston SJ; Richards MA; Bentley AE; Smith P; Rubens RD
    Eur J Cancer; 1993; 29A(11):1513-8. PubMed ID: 8217354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
    Cocconi G; Di Blasio B; Boni C; Bisagni G; Ceci G; Rondini E; Bella M; Leonardi F; Savoldi L; Camisa R; Bruzzi P
    Cancer; 2002 Jul; 95(2):228-35. PubMed ID: 12124820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tamoxifen and combination chemotherapy as adjuvant treatment in postmenopausal women with breast cancer.
    Wallgren A; Baral E; Beling U; Carstensen J; Friberg S; Glas U; Kaigas M; Skoog L
    Recent Results Cancer Res; 1984; 96():197-203. PubMed ID: 6396775
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of advanced breast cancer with aminoglutethimide--response after previous tamoxifen treatment.
    Bezwoda WR; Derman DP; Browde S; Goss G; Lange M
    S Afr Med J; 1984 Sep; 66(10):372-4. PubMed ID: 6484759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Responses to chemotherapy or chemohormonal therapy in advanced breast cancer patients treated previously with adjuvant chemotherapy. A subset analysis of CALGB Study 8081.
    Kardinal CG; Perry MC; Korzun AH; Rice MA; Ginsberg S; Wood WC
    Cancer; 1988 Feb; 61(3):415-9. PubMed ID: 3338011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII.
    Crivellari D; Bonetti M; Castiglione-Gertsch M; Gelber RD; Rudenstam CM; Thürlimann B; Price KN; Coates AS; Hürny C; Bernhard J; Lindtner J; Collins J; Senn HJ; Cavalli F; Forbes J; Gudgeon A; Simoncini E; Cortes-Funes H; Veronesi A; Fey M; Goldhirsch A
    J Clin Oncol; 2000 Apr; 18(7):1412-22. PubMed ID: 10735888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.